{"filings":[{"id":92163,"accession_number":"0001193125-26-160421","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Lyra Therapeutics terminates Waltham sublease; pays $2.1M termination fee","event_type":"other_material","confidence":"high","bullets":["Termination of sublease for 23,704 sq ft at 880 Winter Street, Waltham, MA, effective March 31, 2026.","Company pays $2,100,000 termination payment; rent obligations ceased January 31, 2026.","Upon surrender and payment, RVAC Medicines will release $600,501 letter of credit security deposit.","Sublease originally dated December 21, 2023; premises must be surrendered by May 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92162,"accession_number":"0001193125-26-150441","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Lyra Therapeutics terminates two leases, forfeits $1.4M deposits and pays $2.5M in fees","event_type":"other_material","confidence":"high","bullets":["Watertown lease (22,343 SF): forfeits $302,514.84 LC deposit + pays $1M modification; lease ends May 31, 2026.","Waltham lease (28,858 SF): forfeits $1,089,389 LC deposit + pays $1.5M termination fee; lease ends May 31, 2026.","Contingent: if Sale Transaction closes, Lyra pays 10% of Net Cash up to $1.5M.","Rent obligations ceased Jan 31, 2026 (Watertown) and Mar 31, 2026 (Waltham)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102791,"accession_number":"0001193125-26-108439","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lyra Therapeutics to suspend trading on Nasdaq March 17 after delisting appeal withdrawal","event_type":"other_material","confidence":"high","bullets":["Company withdrew appeal of February 2, 2026 Nasdaq delisting determination.","Nasdaq confirmed suspension of common stock trading at open on March 17, 2026.","Nasdaq will file Form 25 with SEC after internal procedural periods elapse.","No trading halt or additional compliance period cited; delisting is final."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102790,"accession_number":"0001193125-26-083251","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["2.04"],"status":"ready","headline":"Lyra Therapeutics receives default notice for $484K unpaid rent; wind-down continues","event_type":"other_material","confidence":"high","bullets":["Received default notice from sublessor RVAC on Feb 23, 2026 for unpaid rent at Waltham office.","Aggregate unpaid rent totals $484,431.92 as of the notice date.","Company previously announced ceasing operations and wind-down on Jan 12, 2026.","Proposed sublease termination with Jan 31, 2026 surrender, but parties could not agree.","No assurance that obligations can be resolved outside of a bankruptcy process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102789,"accession_number":"0001193125-26-041191","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell","event_type":"other_material","confidence":"high","bullets":["Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.","Nasdaq also cites non-compliance with minimum $2.5M equity listing rule.","Company has requested hearing to appeal delisting; stay in effect pending panel decision.","CEO and CFO now consultants; no ongoing operations after workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102788,"accession_number":"0001193125-26-009772","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.05","5.02","8.01"],"status":"ready","headline":"Lyra suspends LYR-210 development, lays off nearly all staff; CEO/CFO become consultants","event_type":"other_material","confidence":"high","bullets":["Board approved plan to suspend LYR-210 development and reduce workforce affecting substantially all employees, effective Jan 12, 2026.","CEO Dr. Maria Palasis and CFO Jason Cavalier terminated; they signed consulting agreements with monthly fees of $78,125 and $55,555.50, respectively.","Cash and equivalents $22.1M as of Sep 30, 2025; expected runway extended to Q3 2026.","Engaged SSG Capital Advisors to explore strategic alternatives; no assurance of any transaction.","Positive ENLIGHTEN 2 Phase 3 data for LYR-210 (June 2025) but capital constraints force halt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119022,"accession_number":"0001193125-25-277515","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics reports Q3 net loss $6.0M, plans new Phase 3 trial for LYR-210","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $22.1M at Sep 30, 2025; cash runway into Q3 2026.","Net loss for Q3 2025 was $6.0M, down from $11.9M in Q3 2024.","R&D expenses decreased 32% to $4.0M; G&A decreased 43% to $2.2M due to cost reductions.","Planning confirmatory Phase 3 trial of LYR-210 for CRS without nasal polyps following FDA meeting.","Presented positive ENLIGHTEN 2 Phase 3 results at AAO-HNS meeting in October 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":391000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135567,"accession_number":"0001193125-25-195384","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lyra Therapeutics posts corporate presentation; content not detailed in filing extract","event_type":"other","confidence":"low","bullets":["Corporate presentation posted on Sept 4, 2025, on Lyra Therapeutics website.","Company ticker: LYRA (NASDAQ). No other specific updates provided in this filing.","Presentation may be used in investor discussions; details not available from form text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135566,"accession_number":"0001193125-25-186437","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lyra Therapeutics receives Nasdaq deficiency notice for equity below $2.5M minimum","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity as of June 30, 2025 was ~$1.6M, below the $2.5M continued listing requirement.","Company has 45 calendar days (until October 4, 2025) to submit a plan to regain compliance to Nasdaq.","If plan is accepted, Nasdaq may grant up to 180 additional calendar days to evidence compliance.","Failure to regain compliance could lead to delisting; Company may appeal to a Nasdaq Hearings Panel.","No immediate effect on listing or trading of common stock under symbol LYRA on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135565,"accession_number":"0000950170-25-107339","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.","Cash $29.8M at June 30, 2025; $5.0M gross financing extends runway into Q3 2026.","ENLIGHTEN 2 Phase 3 met primary endpoint: 3CS improvement -1.13 (p=0.0078) at week 24; key secondary endpoints also met.","Preparing for Type C meeting with FDA in H2 2025 to align on NDA submission path for LYR-210 in CRS without nasal polyps.","Completed 1-for-50 reverse stock split in May; regained Nasdaq minimum bid compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":366000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135564,"accession_number":"0001193125-25-171647","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Executive Chairman Harlan Waksal departs Lyra; CEO Palasis becomes Chair","event_type":"leadership","confidence":"high","bullets":["Harlan W. Waksal's employment terminated effective August 1, 2025; he resigned from Board.","Dr. Waksal eligible for severance per employment agreement upon signing separation and release.","Maria Palasis, President & CEO, appointed Chair of the Board effective immediately.","Jim Tobin remains as Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152563,"accession_number":"0001193125-25-150301","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lyra Therapeutics raises $5M upfront (up to $15M with warrant exercise) in equity offering","event_type":"other_material","confidence":"high","bullets":["Upfront gross proceeds of $5.0M from sale of 423,372 shares (or pre-funded warrants) at $11.81 per share+private warrant.","Additional up to $9.8M if private warrants (846,744 shares at $11.56) exercised fully; warrants expire 24 months after resale registration effective.","Net proceeds ~$4.3M after placement agent fees (7% cash fee plus 6.5% on future warrant exercises).","Proceeds to be used for working capital and potential clinical development/manufacturing of LYR-210 for chronic rhinosinusitis.","Company previously terminated ~87 employees after failed ENLIGHTEN 1 Phase 3 trial and faces going concern risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152562,"accession_number":"0001193125-25-144151","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lyra regains Nasdaq minimum bid price compliance after 12-day streak above $1.00","event_type":"regulatory","confidence":"high","bullets":["Received notice from Nasdaq on June 13, 2025, confirming compliance with Listing Rule 5550(a)(2).","Common stock maintained minimum bid price of $1.00 for 12 consecutive business days (May 28 - June 12, 2025).","The matter is now closed; no further action required from Nasdaq on this issue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152561,"accession_number":"0001193125-25-137418","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lyra posts corporate presentation; no financial results disclosed","event_type":"other_material","confidence":"low","bullets":["Filing indicates presentation posted to website for investor discussions.","No specific financial or operational updates contained in the 8-K.","Presentation likely contains pipeline and strategy overview; details not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152560,"accession_number":"0001193125-25-132774","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"Lyra Therapeutics reports positive ENLIGHTEN 2 Phase 3 trial: LYR-210 meets primary endpoint in CRS (p=0.0078)","event_type":"other_material","confidence":"high","bullets":["ENLIGHTEN 2 met primary endpoint: LYR-210 improved 3CS composite score vs sham at 24 weeks (-1.13, p=0.0078) in non-polyp patients.","Key secondary endpoints met in full population: 3CS (p=0.0209) and SNOT-22 (-8.7, p=0.0101) at 24 weeks; SNOT-22 improvement seen from week 4.","LYR-210 well-tolerated with safety similar to sham; pooled analysis in 64 nasal polyp patients showed positive trends in multiple endpoints.","Company plans to align with FDA on NDA submission in non-polyp patients and continue development in nasal polyp patients.","Effective May 27, 2025, company effected a 1-for-50 reverse stock split (ticker unchanged LYRA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152559,"accession_number":"0001193125-25-122485","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Lyra Therapeutics approves 1-for-50 reverse stock split, effective May 27","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse-split authority at 1-for-10 to 1-for-50 range; Board set final ratio at 1-for-50.","Reverse split effective 5:00 p.m. ET May 27, 2025; split-adjusted trading starts May 28 under symbol LYRA.","No fractional shares issued; holders receive cash payment based on May 27 closing price.","CUSIP changes to 55234L204 after split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152558,"accession_number":"0000950170-25-064475","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics reports Q1 net loss of $8.5M; ENLIGHTEN 2 top-line results expected Q2 2025","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.5M ($0.13 per share) vs. $22.5M ($0.35) in Q1 2024; cash burn reduced YoY.","Cash & equivalents $31.7M at March 31, 2025, down from $40.6M at Dec 31, 2024.","Topline Phase 3 ENLIGHTEN 2 data for LYR-210 in CRS expected in Q2 2025; ~65 polyp patients across both ENLIGHTEN trials.","Plans a reverse stock split to comply with Nasdaq $1.00 minimum bid; stockholder vote on May 14, 2025.","R&D expenses fell to $4.9M from $18.2M YoY, driven by completion of BEACON and ENLIGHTEN 1 trials and May 2024 workforce reduction."],"consensus_eps_estimate":-6.9702,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":183000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171380,"accession_number":"0000950170-25-038742","cik":1327273,"company_name":"Lyra Therapeutics, Inc.","ticker":"LYRA","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Lyra Therapeutics reports FY2024 net loss $93.4M; ENLIGHTEN 2 top-line data expected Q2 2025","event_type":"other_material","confidence":"high","bullets":["Net loss for FY2024 was $93.4M ($1.43 diluted EPS) vs $62.7M in FY2023; cash $40.6M as of Dec 31, 2024.","Top-line results from ENLIGHTEN 2 Phase 3 trial of LYR-210 in CRS expected in Q2 2025.","Positive post-hoc data from ENLIGHTEN 1 extension in polyp cohort; FDA alignment on registration path for CRSwNP.","Planned reverse stock split to maintain Nasdaq listing; requires shareholder approval in Q2 2025.","R&D expenses decreased to $43.8M from $48.0M due to trial completions and workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}